Taysha Gene Therapies (TSHA) Assets Average: 2022-2025
Historic Assets Average for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $324.9 million.
- Taysha Gene Therapies' Assets Average rose 70.75% to $324.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $324.9 million, marking a year-over-year increase of 70.75%. This contributed to the annual value of $166.5 million for FY2024, which is 11.40% up from last year.
- Taysha Gene Therapies' Assets Average amounted to $324.9 million in Q3 2025, which was up 37.78% from $235.8 million recorded in Q2 2025.
- Taysha Gene Therapies' Assets Average's 5-year high stood at $324.9 million during Q3 2025, with a 5-year trough of $91.6 million in Q2 2023.
- In the last 3 years, Taysha Gene Therapies' Assets Average had a median value of $170.3 million in 2024 and averaged $176.2 million.
- As far as peak fluctuations go, Taysha Gene Therapies' Assets Average slumped by 40.60% in 2023, and later skyrocketed by 92.96% in 2024.
- Quarterly analysis of 4 years shows Taysha Gene Therapies' Assets Average stood at $118.9 million in 2022, then surged by 55.00% to $184.2 million in 2023, then fell by 7.58% to $170.3 million in 2024, then surged by 70.75% to $324.9 million in 2025.
- Its last three reported values are $324.9 million in Q3 2025, $235.8 million for Q2 2025, and $149.4 million during Q1 2025.